Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$20.21 USD
+0.84 (4.34%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $20.39 +0.18 (0.89%) 5:30 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
Pacira (PCRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$41.78 | $57.00 | $25.00 | 115.69% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Pacira comes to $41.78. The forecasts range from a low of $25.00 to a high of $57.00. The average price target represents an increase of 115.69% from the last closing price of $19.37.
Analyst Price Targets (9 )
Broker Rating
Pacira currently has an average brokerage recommendation (ABR) of 1.56 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, five are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 55.56% and 33.33% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 6 | 7 | 7 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 1 | 1 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.56 | 1.56 | 1.33 | 1.30 | 1.30 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/9/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
7/3/2024 | Not Identified | Not Identified | Strong Buy | Hold |
7/2/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
7/2/2024 | H.C. Wainwright & Co. | Oren Livnat | Strong Buy | Strong Buy |
5/7/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
5/7/2024 | Raymond James | Gary Nachman | Moderate Buy | Moderate Buy |
3/1/2024 | Truist Securities | Leszek Sulewski | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.56 |
ABR (Last week) | 1.56 |
# of Recs in ABR | 9 |
Average Target Price | $41.78 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 146 of 252 |
Current Quarter EPS Est: | 0.73 |